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Effect of ambient particulate matter exposure
on hemostasis
EMILY COZZI, CHRISTOPHER J. WINGARD, WAYNE E. CASCIO, ROBERT B. DEVLIN,
JEREMY J. MILES, APRIL R. BOFFERDING, ROBERT M. LUST, MICHAEL R. VAN SCOTT, and
RUTH ANN HENRIKSEN
GREENVILLE AND RESEARCH TRIANGLE PARK, NC

Epidemiological studies have linked levels of particulate matter (PM) in ambient
air to cardiovascular mortality and hospitalizations for myocardial infarction (MI)
and stroke. Thrombus formation plays a primary role in potentiating acute cardiovascular events, and this study was undertaken to determine whether pulmonary exposure to PM alters hemostasis. PM was collected from the Chapel Hill,
NC airshed and was administered to mice by intratracheal instillation at a dose
previously shown to exacerbate myocardial ischemia-reperfusion injury. Twenty-four hours after exposure, an increase occurred in the number of circulating
platelets and plasma concentrations of fibrinogen and soluble P-selectin. The
concentration of tissue factor pathway inhibitor (TFPI) in plasma was decreased,
whereas the plasma concentration of plasminogen activator inhibitor (PAI-1)
was increased. Consistent with these observations, bleeding time from a tail-tip
transection was shortened. These results provide evidence that PM exposure
alters hemostasis in otherwise healthy animals and may thereby promote clot
formation and impede clot resolution in susceptible individuals. The results also
establish definite hemostatic endpoints that can be used to further investigate
the effects of dose and particle characteristics on the toxicity of ambient particles. (Translational Research 2007;149:324 –332)
Abbreviations: CBC ⫽ complete blood count; ELISA ⫽ enzyme-linked immunosorbent assay; ICR
⫽ Institute for Cancer Research; MI ⫽ myocardial infarction; PAI-1 ⫽ plasminogen activator
inhibitor; PBS ⫽ phosphate-buffered saline; PM ⫽ particulate matter; SE ⫽ standard error; sPselectin ⫽ soluble P-selectin; TAT ⫽ thrombin/antithrombin; TF ⫽ tissue factor; TFPI ⫽ tissue factor
pathway inhibitor; tPA ⫽ tissue-type plasminogen activator; US-EPA ⫽ United States Environmental
Protection Agency

lobal epidemiological studies have linked
ambient particulate matter (PM) exposure to
cardiac arrhythmia, myocardial infarction
(MI), cardiac arrest, heart failure, and mortality because
of ischemic heart disease.1–3 Empirical evidence collected over the past decade also indicates that airborne

G

PM can affect cardiovascular function and may thereby
contribute to the pathogenesis of cardiovascular disease.4 –12
Ambient PM comprises a heterogeneous mixture of
substances, including carbon, metals, nitrates, sulfates,
organic compounds, and components of biogenic ori-
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gin.13,14 PM is derived from several different sources,
including combustion products from gasoline and diesel engines, coal- and oil-fired power plants, biomass
burning (eg, fireplaces and forest fires), and natural
sources such as wind-blown dust or crushing of crustal
materials.13,15–18 The US-EPA, currently regulates PM
levels on the basis of mass in 2 size ranges: “coarse”
PM (2.5–10 microns in diameter) and “fine” PM (0.1–
2.5 microns in diameter).13 However, increasing attention is being placed on smaller “ultrafine” particles,
with a diameter of less than 0.1 micron.13 Although
these particles contribute very little to PM mass, they
dominate particle number and surface area metrics.13,19
Furthermore, some have suggested that these smaller
particles can more readily exit the lung, where they
may directly affect cells and organs of the cardiovascular system.20
Inhalation of PM has been shown to activate pulmonary endothelium, macrophages, and neutrophils.21–23
Pulmonary inflammation acts as a catalyst for subsequent systemic inflammation.21,22,24 Studies in humans
and animals have demonstrated that PM increases the
release of neutrophils from bone marrow and the number of subsequently circulating neutrophils.19,25 Relocation from an environment with high PM levels to one
with negligible PM reverses this effect.26 PM exposure
has also been shown to increase C-reactive protein
expression, plasma viscosity, and the progression of
atherosclerotic lesions.13,22,27–30 Furthermore, exposure
to concentrated ambient particles has been associated
with increased oxidative stress, altered vascular reactivity, and alterations in hemostasis, which are strongly
associated with adverse cardiovascular effects.10,31–34
Recent studies indicate that exposure to PM also
promotes thrombus formation. Nemmar et al20 have
shown that PM from diesel exhaust activates platelets
and promotes femoral venous thrombosis in a dosedependent manner in hamsters. Likewise, Radomski
et al35 observed that exposure to carbon particles augmented thrombosis in rats. Addition of these particles
directly to human platelets induced platelet aggregation
via adenosine 5=-diphosphate-, matrix metalloproteinase-, or protein kinase C-dependent pathways.35 This
study was undertaken to elucidate effects of ambient
particulate matter on systemic factors involved in hemostasis and thereby to define discrete endpoints that
can be used to further investigate the toxicity of airborne particles.
MATERIALS AND METHODS
Animals. For this study, 6- to 10-week-old male Institute
for Cancer Research (ICR) mice were obtained from Harlan
(Indianapolis, Ind), housed in microisolation, and cared for by
the East Carolina University Comparative Medicine staff. All
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protocols conformed to the standards in the National Institutes of Health’s “Guide for the Care and Use of Laboratory
Animals” and were approved by the East Carolina University
Institutional Committee on the Care and Use of Laboratory
Animals.
Particle collection and extraction. Particles were collected as described by Cozzi et al.10 Briefly, particles were
collected over 7-day periods, during October 2002, in Chapel
Hill, NC with a ChemVol High Volume Cascade Impactor
(Rupprecht and Patashnick Co., Inc., East Greenbush, NY).
Particles (less than 0.15 m in diameter) were collected onto
G5300 filters (Monandock Non-Wovens LLC, Mt. Pocono,
Penn), dried under sterile conditions, and stored at ⫺80°C
until extracted. Particles were extracted by prewetting the
filter with 70% ethanol, and endotoxin-free water was added
to yield a total volume of 40 mL. Extraction efficiency was
65–70%. The substrate–water solution was sonicated, and the
particle extract was concentrated by lyophilization and stored
at ⫺80°C. Extracts were reconstituted to a concentration of 5
mg/mL in water and stored at ⫺80°C. Four consecutive
weeks of extracts were pooled into monthly batches. These
particles exhibit a total carbon mass fraction of just over 22%;
high levels of arsenic, bromide, selenium, sulfur, and zinc;
and low levels of iron and titanium (unpublished data). Particle endotoxin levels were measured with a chromogenic
limulus amebocyte lysate endpoint assay (QCL-1000; Cambex, Rockland, Me) according to kit instructions. No detectable levels of endotoxin were found on the particles.
Particulate exposure. Mice were exposed to PM as described by Cozzi et al.10 Briefly, mice were anesthetized with
vapors from isoflurane/propanediol and a suspension of 100 g
of PM in 100 L of sterile phosphate-buffered saline (PBS)
(composition in mM: NaCl, 137; NaH2PO4, 10; KH2PO4, 1.47;
KCl, 2.7; pH adjusted to 7.4) was prepared and delivered by
intratracheal instillation. This dose of PM was previously shown
to elicit pulmonary and cardiovascular effects in ICR mice.10
Vehicle-exposed mice received 100 L of sterile PBS.
Complete blood count (CBC). Twenty-four hours after
exposure, a cardiac blood draw was performed in mice euthanized by intraperitoneal injection of sodium pentobarbital
as adapted from Hoff et al.36 Blood was drawn to a total
volume of 1 mL using a 25-gauge needle attached to a 1-mL
syringe containing 100 L of 3.8% sodium citrate as an
anticoagulant. A CBC was determined on whole blood using
a Coulter Counter (Beckman Coulter, Fullerton, Calif). Cell
counts were corrected for anticoagulant dilution, averaged
between groups, and reported.
Platelet/monocyte interaction. Blood collected 24 h after exposure from a separate set of mice was placed in
PGE1-K2EGTA anticoagulant tubes and then divided for subsequent analyses. For flow cytometry analysis of CD41, red
blood cells were lysed by adding Optilyse C (Beckman
Coulter) in a 1:1 ratio and 50 L of the blood/Optilyse C
solution was incubated with a fluorescent-conjugated antibody against CD41 (anti-mouse CD41-FITC; BD Biosciences, San Jose, Calif) or a matched isotype control antibody (IgG1-FITC; BD Biosciences). The monocyte cell gate
was determined by forward- and side-scatter parameters. Flu-
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orescence within this gate was analyzed by flow cytometry
(FACScan; Becton Dickinson, San Jose, Calif), and mean
fluorescence intensity was calculated and reported.
Plasma fibrinogen levels. Whole blood remaining after
CBC analyses was centrifuged at 5000 g for 10 min, and
plasma was removed. Plasma fibrinogen levels in fresh
plasma were determined by a modified thrombin time as
described by Clauss et al.37 Briefly, 100 L of diluted plasma
was incubated at 37°C within the Coag-A-Mate XM coagulation timer (Biomerieux, Durham, NC) before the addition of
100 L of Fibriquik thrombin reagent (Biomerieux) to induce
coagulation. Clotting times were converted to fibrinogen level
based on a human fibrinogen standard curve. Mean fibrinogen
levels for each mouse group were calculated and reported.
Plasma thrombin/antithrombin (TAT) levels. Twenty-four
hours after exposure, plasma TAT complex concentrations
were determined with a human TAT complex-specific sandwich enzyme-linked immunosorbent assay (ELISA) known to
cross-react with mouse TAT antigen according to kit instructions (Enzygnost kit; Dade Behring, Marburg, Germany).38,39
Briefly, 50 L of citrated plasma were incubated in 96 well
plates coated with human thrombin-specific antibody. After
addition of a peroxidase conjugated antibody to human antithrombin and color development, the optical density of the
plate was read at 492 nm using a spectrophotometer (SmartSpec 3000; Bio-Rad, Hercules, Calif). A negative control
containing sample buffer was also used to establish a background spectrophotometer reading at 492 nm, which was
subtracted from sample readings, and TAT complex concentrations were determined based on a human TAT complex
standard curve (2– 60 ng/mL) supplied with the kit. Mean
plasma TAT concentrations were calculated and reported.
ELISAs for plasma soluble P-selectin (sP-selectin),
plasma tissue factor pathway inhibitor (TFPI), plasma tissue-type plasminogen activator (tPA), and plasminogen
activator inhibitor (PAI-1). Blood collected via cardiac punc-

ture was placed in collection tubes containing 7.5% EDTA(K3) anticoagulant (Kendall Monoject 10.25 ⫻ 50 mm;
Tyco Healthcare Group LP, Mansfield, Mass) and centrifuged
at 5000 g for 10 min to obtain plasma. Plasma sP-selectin,
tPA, and PAI-1 concentrations were determined by using
commercially available ELISA kits according to the manufacturers’ instructions (Quantikine kit; R&D systems, Minneapolis, Minn; Molecular Innovations, Southfield, Mich).
Plasma TFPI concentrations were determined by coating 96
well plates with 1:20 diluted plasma in 1% bovine serum
albumin in PBS. Rabbit anti-mouse TFPI IgG (1:500; American Diagnostica, Inc., Stamford, Conn), goat anti-rabbit IgG
peroxidase conjugate (1:12,000; Sigma-Aldrich, St. Louis,
Mo), and 3,3= 5,5= Tetramethylbenzidine substrate reagent
(BD Biosciences) were used for detection. Plate absorbance
was measured at 450 nm using a microplate reader (Benchmark Microplate Reader; Bio-Rad). Specificity of the antiTFPI antibody was confirmed by immunoprecipitation as
described by Michielsen et al.40
Bleeding time determination by tail-tip transaction. Analysis of bleeding from an induced injury was conducted as
described by Sato et al.41 Twenty four hours after exposure,

mice were anesthetized with sodium pentobarbital (50 mg/kg
initial dose, 30 mg/kg if supplemental doses were needed),
and tail-tips, 5 mm from their distal end, were surgically
transected using a scalpel blade. Tails were immediately
placed in a tube containing 10 mL of saline warmed to 37°C,
and a timer was started. The bleeding time was recorded as
the time required for initial stoppage of blood flow. Average
bleeding times were calculated and reported for each mouse
group. Overall, 20 min after tail transection, blood collected
in saline was hemolyzed and the absorbance at 546 nm was
used to determine blood volume loss.
Statistics. Values were reported as mean ⫾ standard error
(SE). Differences between groups were compared using the
Student t-test for unpaired observation or analysis of variance
with the Fisher exact test for least significant difference. In all
cases, a P value of less than 0.05 was used to indicate
statistical significance between groups.
RESULTS
Particulate matter effects on circulating blood cell
counts. Total leukocyte counts decreased 24 h after PM

exposure (vehicle, 5620 ⫾ 310 cells/mL whole blood;
PM, 4608 ⫾ 331 cells/mL whole blood; P ⫽ 0.026).
These results were consistent with previous findings
and confirmed effective delivery of PM.10 It should be
noted that, in some animal studies, increases in circulating polymorphonuclear cells with PM exposure have
been reported.22,42 For shorter time intervals after PM
exposure, it has been reported that circulating neutrophils enter the lungs, which could explain the reduction
in total leukocyte counts observed.43
In contrast, circulating platelet numbers in exposed
mice increased slightly compared with vehicle controls
(Fig 1, A). As PM exposure did not alter circulating RBC
number (vehicle, 818,400 ⫾ 168,465 cells/mL whole
blood; PM, 824,333 ⫾ 139,081 cells/mL whole blood;
P ⫽ 0.43), hemoglobin (vehicle, 13.1 ⫾ 0.3 g/dL; PM,
13.1 ⫾ 0.2 g/dL; P ⫽ 0.95), or hematocrit (vehicle,
41.4 ⫾ 1.0%; PM, 41.8 ⫾ 0.9%; P ⫽ 0.39), the results
indicate specific effects on neutrophils and circulating
platelets.
Effect of particulate matter on platelet and endothelial
activation. sP-selectin may be released by both acti-

vated platelets and endothelial cells.44,45 PM exposure
significantly increased plasma sP-selectin levels 24 h
after exposure (Fig 1, B). Interaction of platelets and
monocytes was examined as a more specific indicator
of platelet activation.46 Platelets were labeled with a
fluorescent-conjugated antibody specific for mouse
platelet glycoprotein IIb (CD41), and association with
monocytes was then analyzed by flow cytometry. PM
exposure did not alter the number of CD41-positive
platelets within the monocyte gate (Fig 2), indicating
that PM exposure did not increase binding between
platelets and monocytes.
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Fig 1. Total platelet number and plasma sP-selectin levels 24 h after
exposure. Mice were exposed to vehicle or 100 g of PM by
intratracheal instillation. (A) Blood was drawn via cardiac puncture
24 h after exposure, and a CBC was performed on each whole-blood
sample. Values represent mean platelet numbers ⫾ SE, n ⫽ 11
vehicle control and n ⫽ 9 PM exposed animals. (B) Blood was drawn
via cardiac puncture 24 h after exposure, and plasma was prepared
and assayed with a commercially available mouse specific sP-selectin
ELISA kit. Values represent mean ⫾ SE, n ⫽ 6 in each group,
repeated in duplicate.

Effect of particulate matter on circulating coagulation
proteins. Fibrinogen is the soluble precursor of fibrin,

which plays a central role in platelet aggregation and
clot formation.47 Plasma fibrinogen levels from blood
samples obtained via cardiac puncture 24 h after PM or
vehicle exposure were significantly increased compared with the vehicle control group (Fig 3).
Thrombin is a serine protease that not only converts
soluble fibrinogen into insoluble fibrin, but also it promotes platelet aggregation during clot formation.48
Thrombin activity is inhibited when antithrombin binds
irreversibly to thrombin forming a TAT complex.49 As
thrombin is the terminal protease in the coagulation
cascade, analysis of TAT complex concentrations
within the plasma serves as an indication of coagulation
pathway activation.50 Plasma TAT concentrations were
unchanged 24 h after PM exposure (Fig 4), indicating
the lack of ongoing thrombin generation.
TFPI, a glycoprotein released by endothelial cells,
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Fig 2. Circulating platelet/monocyte interaction 24 h after PM or
vehicle exposure. Blood was drawn via cardiac puncture 24 h after
exposure. Platelets in each whole-blood sample were labeled with a
mouse-specific fluorescent-conjugated antibody against CD41. (A,
gate R1) Flow cytometry was performed, and the monocyte population
was gated based on forward and side scatter properties. (B) CD41
represents mean florescence intensity within the monocyte gate. Values
represent mean ⫾ SE, n ⫽ 6 in each group, repeated in duplicate.

Fig 3. Plasma fibrinogen levels 24 h after PM or vehicle exposure.
Blood was drawn via cardiac puncture 24 h after exposure, and
plasma was prepared. Plasma fibrinogen levels were determined by a
modified thrombin time. Values represent mean fibrinogen concentrations ⫾ SE, n ⫽ 11 vehicle control and 9 PM exposed animals.
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Fig 4. Plasma TAT concentrations 24 h after vehicle or PM exposure. Blood was drawn via cardiac puncture 24 h after exposure, and
plasma was prepared. TAT plasma concentrations were determined
with a commercially available ELISA kit. Values represent mean
TAT concentrations ⫾ SE, n ⫽ 10 in each group.

Fig 5. Plasma TFPI absorbance 24 h after vehicle or PM exposure.
Blood was drawn via cardiac puncture 24 h after exposure, and
plasma was prepared. TFPI concentrations were determined by sandwich ELISA. Values represent mean TFPI concentration ⫾ SE, n ⫽
7 vehicle control and 6 PM exposed animals, repeated in triplicate.

inhibits TF-initiated clotting by binding factor Xa and
the TF/VIIa complex, thus inhibiting subsequent
thrombin production.51,52 Plasma TFPI levels were decreased significantly 24 h after PM exposure when
compared with vehicle control (Fig 5).
Effect of particulate matter on the fibrinolytic pathway. Tissue-tPA converts plasminogen into the active

protease plasmin, which leads to degradation of fibrin
and subsequent vascular thrombus dissolution.53 PM
exposure did not change circulating tPA levels 24 h
after exposure (Fig 6, A). PAI-1 is a member of the
serine protease inhibitor family and is the primary
inhibitor of tPA.54 Thus, PAI-1 serves to inhibit fibrinolysis and clot dissolution. PM exposure significantly
increased circulating PAI-1 levels above vehicle 24 h
after exposure (Fig 6, B).

Fig 6. Plasma tPA absorbance and PAI-1 concentrations 24 h after
vehicle or PM exposure. Blood was drawn via cardiac puncture 24 h
after exposure, and plasma was prepared. Tissue plasminogen activator concentrations were determined with a commercially available
ELISA kit and mean sample absorbance ⫾ SE is shown, assays
repeated in duplicate, n ⫽ 21, vehicle control and 17 PM exposed
animals (A). PAI-1 concentrations were determined with a commercially available ELISA kit (B). Values represent mean PAI-1 concentrations ⫾ SE, n ⫽ 13 vehicle control and 8 PM exposed animals,
repeated in duplicate.

In vivo analysis of particulate matter exposure on he-

In mice, the length of time that blood flows
from an induced vascular injury is indicative of the
levels of coagulation factors as well as of platelet and
endothelial activity.55 Bleeding time from a tail-tip
transection was therefore assessed as an in vivo indicator of hemostasis. Mice were exposed to PM or vehicle,
and 24 h after exposure, tail-tips were transected and
bleeding times were measured. Bleeding times were
significantly shortened after PM exposure when compared with vehicle controls (Fig 7), indicating that the
propensity for clot formation was enhanced. The total
blood loss 20 min after tail-tip transection was not
significantly different between PM exposed and control
groups (results not shown).
mostasis.
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Fig 7. Bleeding times 24 h after vehicle or PM exposure. Tail-tips
were surgically transected 24 h after exposure and bleeding time was
measured. Values for bleeding time represent mean bleeding time ⫾
SE, n ⫽ 12 in each group.

DISCUSSION

Studies have linked human exposure to air pollution
with increased cardiovascular mortality because of
ischemic heart disease, heart failure, arrhythmia, and
cardiac arrest.13 Increases in air pollution have also
been associated with an increased incidence of hospitalization for these same cardiovascular complications
24 h after peak ambient pollution levels.13 Populationbased studies by Liao et al56 have shown that shortterm exposure to coarse PM was positively associated
with plasma inflammatory and hemostatic risk factors
for cardiovascular disease. Although evidence suggesting a link between pollution and hypercoagulability is
accumulating, there is still little evidence to suggest
that PM directly affects the clotting cascade in otherwise healthy animals. The results of this study provide
evidence that pulmonary exposure to ambient PM induces acute-phase inflammation and alters hemostatic
factors associated with blood clot formation and resolution.
Multiple observations from this study support the
concept that exposure to PM induces a state of hypercoagulability conducive to thrombus formation in
healthy animals. The number of circulating platelets,
the concentration of sP-selectin, and fibrinogen in
plasma were increased by PM exposure (Figs 1 and 3).
The amount of TFPI in plasma, which should downregulate the activity of the tissue factor pathway, was
reduced by PM exposure (Fig 5). Plasma tPA level
was unchanged (Fig 6, A), but plasma PAI-1 level was
increased (Fig 6, B), which is expected to decrease the
activity of available tPA. The time for coagulation to
occur was decreased after PM exposure, as indicated by
shorter bleeding times after tail-tip transection (Fig 7).
Thus, PM exposure induced multiple procoagulant
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changes predicted to contribute to an environment conducive to thrombus formation.
Alterations in platelet number and function play a
pivotal role in the pathogenesis of acute coronary syndromes.57,58 Increases in platelet number, size, and
activity are considered risk factors for MI.59 – 61 Reed
et al15 has shown that total platelet numbers were
increased in rodents exposed to hardwood smoke by
whole-body inhalation. The increase in platelet number
observed in response to PM exposure was consistent
with these earlier studies, but the increase was small
and unlikely to be clinically relevant by itself. Platelet
activation has also been shown to be altered with PM
exposure. Nemmar et al20 have demonstrated that circulating platelets were directly activated by interacting
with diesel exhaust particles. It should be noted that
some studies have not demonstrated an increase in
circulating platelet number or activity with PM exposure.20,62 This discrepancy could be a result of differences in exposure methods, duration of administration,
dose administered, time of measurement, or innate
characteristics of PM used in those studies. sP-selectin
can facilitate procoagulant activity,44,45,63 and increased sP-selectin levels have been linked to acute
myocardial infarction, peripheral arterial occlusive disease, plaque destabilization, and atrial fibrillation.64 – 68
sP-selectin is typically thought to be an indicator of
platelet activation state. However, Burger et al45 have
demonstrated that the primary source of circulating
P-selectin may be activated endothelial cells. In either
case, sP-selectin levels serve as a marker of an activated vasculature/blood interface that would promote
thrombus formation.
In contrast to the results in this study, Khandoga
et al69 demonstrated that PM administered intravenously did not increase endothelial expression of Pselectin in mice, although sP-selectin was not measured. Their findings may be related to the time of
assessment or the route of administration, resulting in a
lack of appreciable pulmonary inflammation in their
model.13 A link between sP-selectin levels and the
degree of pulmonary inflammation in response to PM
exposure is an interesting concept because it suggests
that the capacity of PM to alter thrombogenic potential
may be linked to a generalized inflammatory condition
as opposed to a specific effect of the particles. More
studies must be conducted to test this hypothesis.
Increased fibrinogen levels have been associated with
the progression of atherosclerotic lesions and are considered a risk factor for future cardiovascular events.47
The results of this study (Fig 3) are consistent with
human ambient particle exposure studies by Ghio
et al,34 in which plasma fibrinogen levels were increased 24 h after particle inhalation. Thus, adminis-
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tration of PM by either inhalation or instillation resulted
in increased fibrinogen levels.
Increased TAT complex concentrations within the
plasma are indicative of activation of the coagulation
pathway.50 In human studies, increased TAT levels
have been linked to MI, unstable angina, and atrial
fibrillation.70 TAT concentrations measured 24 h after
PM exposure were not altered compared with control
values (Fig 4), indicating that at the time point investigated evidence for activation of the coagulation pathway was not detected. These results are in agreement
with those of Nadziejko et al,71 who demonstrated that
inhaled fine PM did not affect plasma TAT levels in
rats at 12 and 24 h post-exposure.
TFPI is a glycoprotein that is released primarily by
activated endothelial cells and acts as a primary inhibitor of clot formation by inhibiting thrombin production.51,52 In this study, plasma TFPI was significantly
decreased after PM exposure (Fig 5). This report is the
first to address the ability of PM to alter TFPI protein
expression. Decreased TFPI levels have recently been
linked to an increased risk of deep vein thrombosis in
humans.72
Occlusion of microvessels in vivo is affected by both
thrombus formation and resolution. Observations indicate that PM exposure may also affect the resolution of
clots through alteration of the fibrinolytic pathway. tPA
converts plasminogen to plasmin, which promotes clot
lysis.73 PAI-1 is the major inhibitor of tPA and thereby
promotes clot retention.54 Although plasma tPA levels
were unaltered, plasma PAI-1 levels were increased
significantly, which would be expected to impair fibrinolysis (Fig 6). Increased PAI-1 levels and subsequently impaired fibrinolysis are associated with cardiovascular disease, insulin resistance, and abdominal
obesity.54,73,74 This study is the first demonstration that
PM exposure can alter the expression of inhibitors of
both clot formation and resolution in a procoagulant
manner.
Hemostasis is a balance between coagulation and
fibrinolytic processes.75 Therefore, a tail-tip transection
was performed as an overall indication of the effect of
PM exposure on hemostasis in vivo. In this study, it was
demonstrated that bleeding time was significantly reduced 24 h after PM exposure (Fig 7). Bleeding time is
a function of vascular reactivity, coagulation status, and
platelet function.76 The lack of significant difference in
total blood loss between the experimental and control
groups is consistent with the presence of only a mild
thrombotic tendency in the PM-exposed animals. In
this study, evidence of altered endothelial function includes reduced plasma TFPI, increased sP-selectin, and
increased PAI-1 expression. In addition, it was previously demonstrated that aortic relaxation to acetylcho-

line is impaired 24 h after PM exposure.10 Platelet
number in this model was increased; however, platelet
activation was not detected as evidenced by the absence
of an increase in platelet/monocyte adhesion determined by flow cytometry. Thus, the reduction in bleeding time observed in this model may be due primarily
to endothelial activation and subsequent prothrombotic
alterations in coagulation factors responsible for clot
formation and resolution. It is important to note that
bleeding times have been used extensively to study
pharmacologic, pathophysiologic, and genetic alterations in hemostasis in humans and animals.76 These
results are consistent with studies that have looked
directly at clot formation in vivo. Nemmar et al20 demonstrated that intratracheal diesel exhaust particle
exposure enhanced arterial and venous thrombus formation in an in vivo endothelial injury model. Likewise,
Radomski et al35 showed that exposure to nanoparticles
resulted in increased thrombosis induced by ferric chloride endothelial injury in rat carotid arteries.
Speculations. Taken together, the results of this study
provide evidence that pulmonary exposure to PM alters
thrombogenic potential through effects on clot formation and resolution, which may be particularly relevant
in a setting of preexisting atherosclerotic disease in
which individuals are susceptible to thrombus formation and vessel occlusion. Furthermore, the results define a set of easily measured hemostatic parameters by
which particle exposure time courses and particle toxicity may be further investigated.
The authors thank Martina Bainbridge Christie, Mary Cobb, Shaun
Reece, Dr. Arthur Bode, Howard Stallings III, Dr. Douglas A.
Weidner, Ralph Smith, and Elizabeth Fontenot for technical assistance with this study. This research has been reviewed by the National Health and Environmental Effects Research Laboratory, USEPA, and approved for publication. Approval does not necessarily
reflect policy, and mention of trade names or commercial products
does not constitute endorsement or recommendation for use.

REFERENCES

1. Peters A, Dockery DW, Muller JE, Mittleman MA. Increased
particulate air pollution and the triggering of myocardial infarction. Circulation 2001;103:2810 –5.
2. Peters A, Liu E, Verrier RL, Schwartz J, Gold DR, Mittleman M,
et al. Air pollution and incidence of cardiac arrhythmia. Epidemiology 2000;11:11–7.
3. Pope CA III, Burnett RT, Thurston GD, Thun MJ, Calle EE,
Krewski D, et al. Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of
general pathophysiological pathways of disease. Circulation
2004;109:71–7.
4. Kodavanti UP, Moyer CF, Ledbetter AD, Schladweiler MC,
Costa DL, Hauser R, et al. Inhaled environmental combustion
particles cause myocardial injury in the wistar kyoto rat. Toxicol
Sci 2003;71:237– 45.
5. Bagate K, Meiring JJ, Gerlofs-Nijland ME, Vincent R, Cassee
FR, Borm PJA. Vascular effects of ambient particulate matter

Translational Research
Volume 149, Number 6

6.

7.

8.

9.

10.

11.
12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

instillation in spontaneous hypertensive rats. Toxicol Appl
Pharmacol 2004;197:29 –39.
Tzeng HP, Yang RS, Ueng TH, Lin-Shiau SY, Liu SH. Motorcycle exhaust particulates enhance vasoconstriction in organ
culture of rat aortas and involve reactive oxygen species. Toxicol
Sci 2003;75:66 –73.
Moyer CF, Kodavanti UP, Haseman JK, Costa DL, Nyska A.
Systemic vascular disease in male B6C3F1 mice exposed to
particulate matter by inhalation: studies conducted by the National Toxicology Program. Toxicol Pathol 2002;30:427–34.
Campen MJ, McDonald JD, Gigliotti AP, Seilkop SK, Reed MD,
Benson JM. Cardiovascular effects of inhaled diesel exhaust in
spontaneously hypertensive rats. Cardiovasc Toxicol 2003;3:353–
61.
Wellenius GA, Batalha JR, Diaz EA, Lawrence J, Coull BA,
Katz T, et al. Cardiac effects of carbon monoxide and ambient
particles in a rat model of myocardial infarction. Toxicol Sci
2004;80:367–76.
Cozzi E, Hazarika S, Stallings HW III, Cascio WE, Devlin RB,
Lust RM, et al. Ultrafine particulate matter exposure augments
ischemia-reperfusion injury in mice. Am J Physiol Heart Circ
Physiol 2006;291:H894 –903.
Culic V. Acute risk factors for myocardial infarction. Int J Cardiol. In press.
Sun Q, Wang A, Jin X, Natanzon A, Duquaine D, Brook RD, et al.
Long-term air pollution exposure and acceleration of atherosclerosis
and vascular inflammation in an animal model. JAMA 2005;294:
3003–10.
Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett
M, et al. Air pollution and cardiovascular disease: a statement for
healthcare professionals from the Expert Panel on Population and
Prevention Science of the American Heart Association. Circulation 2004;109:2655–71.
Delfino RJ, Sioutas C, Malik S. Potential role of ultrafine particles in associations between airborne particle mass and cardiovascular health. Environ Health Perspect 2005;113:934 – 46.
Reed MD, Campen MJ, Gigliotti AP, Harrod KS, McDonald JD,
Seagrave JC, et al. Health effects of subchronic exposure to
environmental levels of hardwood smoke. Inhal Toxicol 2006;
18:523–39.
de Kok TM, Driece HA, Hogervorst JG, Briede JJ. Toxicological
assessment of ambient and traffic-related particulate matter: a
review of recent studies. Mutat Res 2006;613:103–22
Wallington TJ, Kaiser EW, Farrell JT. Automotive fuels and
internal combustion engines: a chemical perspective. Chem Soc
Rev 2006;35:335– 47.
Chimonas MA, Gessner D. Airborne particulate matter from
primarily geologic, non-industrial sources at levels below National Ambient Air Quality Standards is associated with outpatient visits for asthma and quick-relief medication prescriptions
among children less than 20 years old enrolled in Medicaid in
Anchorage, Alaska. Environ Res. In press.
Salvi S, Blomberg A, Rudell B, Kelly F, Sandstrom T, Holgate
ST, et al. Acute inflammatory responses in the airways and
peripheral blood after short-term exposure to diesel exhaust in
healthy human volunteers. Am J Respir Crit Care Med 1999;
159:702–9.
Nemmar A, Hoylaerts MF, Hoet PH, Nemery B. Possible mechanisms of the cardiovascular effects of inhaled particles: systemic translocation and prothrombotic effects. Toxicol Lett
2004;149:243–53.
Salvi S, Holgate ST. Mechanisms of particulate matter toxicity.
Clin Exp Allergy 1999;29:1187–94.

Cozzi et al

331

22. Schulz H, Harder V, Ibald-Mulli A, Khandoga A, Koenig W,
Krombach F, et al. Cardiovascular effects of fine and ultrafine
particles. J Aerosol Med 2005;18:1–22.
23. Stenfors N, Nordenhall C, Salvi SS, Mudway I, Soderberg M,
Blomberg A, et al. Different airway inflammatory responses in
asthmatic and healthy humans exposed to diesel. Eur Respir J
2004;23:82– 6.
24. Nurkiewicz TR, Porter DW, Barger M, Castranova V, Boegehold
MA. Particulate matter exposure impairs systemic microvascular
endothelium-dependent dilation. Environ Health Perspect 2004;
112:1299 –306.
25. Mukae H, Vincent R, Quinlan K, English D, Hards J, Hogg JC,
et al. The effect of repeated exposure to particulate air pollution
(PM10) on the bone marrow. Am J Respir Crit Care Med
2001;163:201–9.
26. Sakai M, Sato Y, Sato S, Ihara S, Onizuka M, Sakakibara Y, et al.
Effect of relocating to areas of reduced atmospheric particulate
matter levels on the human circulating leukocyte count. J Appl
Physiol 2004;97:1774 – 80.
27. Peters A, Frohlich M, Doring A, Immervoll T, Wichmann HE,
Hutchinson WL, et al. Particulate air pollution is associated with
an acute phase response in men. Results from the MONICAAugsburg Study. Eur Heart J 2001;22:1198 –204.
28. Peters A. Particles in the outside air increase the risk of cardiovascular diseases. Gesundheitswesen 2005;67(Suppl 1):S79 – 85.
29. Sandhu RS, Petroni DH, George WJ. Ambient particulate matter,
C-reactive protein, and coronary artery disease. Inhal Toxicol
2005;17:409 –13.
30. Verrier RL, Mittleman MA, Stone PH. Air pollution: an insidious
and pervasive component of cardiac risk. Circulation 2002;106:
890 –2.
31. Brook RD, Brook JR, Rajagopalan S. Air pollution: the “heart”
of the problem. Curr Hypertens Rep 2003;5:32–9.
32. Brook RD, Brook JR, Urch B, Vincent R, Rajagopalan S,
Silverman F. Inhalation of fine particulate air pollution and ozone
causes acute arterial vasoconstriction in healthy adults. Circulation 2002;105:1534 – 6.
33. Fabbi P, Ghigliotti G, Brunelli C, Balbi M, Spallarossa P,
Rossettin P, et al. Intense lipid peroxidation in premature clinical
coronary atherosclerosis is associated with metabolic abnormalities. J Lab Clin Med 2004;143:99 –105.
34. Ghio AJ, Hall A, Bassett MA, Cascio WE, Devlin RB. Exposure
to concentrated ambient air particles alters hematologic indices
in humans. Inhal Toxicol 2003;15:1465–78.
35. Radomski A, Jurasz P, onso-Escolano D, Drews M, Morandi M,
Malinski T, et al. Nanoparticle-induced platelet aggregation and
vascular thrombosis. Br J Pharmacol 2005;146:882–93.
36. Hoff J. Methods of blood collection in the mouse. Lab Animal
2000;29:47–53.
37. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957;17:237– 46.
38. Ravanat C, Freund M, Dol F, Cadroy Y, Roussi J, Incardona F,
et al. Cross-reactivity of human molecular markers for detection
of prethrombotic states in various animal species. Blood Coagul
Fibrinolysis 1995;6:446 –55.
39. Leon C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet
C. Key role of the P2Y(1) receptor in tissue factor-induced
thrombin-dependent acute thromboembolism: studies in P2Y(1)knockout mice and mice treated with a P2Y(1) antagonist. Circulation 2001;103:718 –23.
40. Michielsen EC, Diris JH, Hackeng CM, Wodzig WK, Van
Dieijen-Visser MP. Highly sensitive immunoprecipitation
method for extracting and concentrating low-abundance proteins from human serum. Clin Chem 2005;51:222– 4.

332

Translational Research
June 2007

Cozzi et al

41. Sato K, Taniuchi Y, Kawasaki T, Hirayama F, Koshio H,
Matsumoto Y, et al. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa
inhibitor, and warfarin in mice. Jpn J Pharmacol 1998;78:191–7.
42. Kodavanti UP, Schladweiler MC, Ledbetter AD, Hauser R,
Christiani DC, McGee J, et al. Temporal association between
pulmonary and systemic effects of particulate matter in healthy
and cardiovascular compromised rats. J Toxicol Environ Health
A 2002;65:1545– 69.
43. Nemmar A, Hoet PH, Dinsdale D, Vermylen J, Hoylaerts MF,
Nemery B. Diesel exhaust particles in lung acutely enhance experimental peripheral thrombosis. Circulation 2003;107:1202– 8.
44. Andre P. P-selectin in haemostasis. Br J Haematol 2004;126:
298 –306.
45. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003;101:2661– 6.
46. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman
MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface
P-selectin: studies in baboons, human coronary intervention, and
acute myocardial infarction. Circulation 2002;104:1533–7.
47. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in
unstable coronary artery disease. FRISC Study Group. Fragmin
during instability in coronary artery disease. Circulation 1997;
96:4204 –10.
48. Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE,
Laurent GJ. Thrombin is a potent inducer of connective tissue
growth factor production via proteolytic activation of proteaseactivated receptor-1. J Biol Chem 2000;275:35584 –91.
49. Bock PE, Olson ST, Bjork I. Inactivation of thrombin by antithrombin is accompanied by inactivation of regulatory exosite I.
J Biol Chem 1997;272:19837– 45.
50. Sommeijer DW, van Oerle R, Reitsma PH, Timmerman JJ,
Meijers JC, Spronk HM, et al. Analysis of blood coagulation
in mice: pre-analytical conditions and evaluation of a
home-made assay for thrombin-antithrombin complexes.
Thromb J 2005;3:12.
51. Brodin E, Iversen N, Hansen JB. Impact of native VLDL on
tissue factor pathway inhibitor in endothelial cells and interactions between TFPI and lipoprotein lipase. J Lab Clin Med
2006;147:167–73.
52. Walker CP, Royston D. Thrombin generation and its inhibition:
a review of the scientific basis and mechanism of action of
anticoagulant therapies. Br J Anaesth 2002;88:848 – 63.
53. Ishii-Watabe A, Uchida E, Mizuguchi H, Hayakawa T. On the
mechanism of plasmin-induced platelet aggregation. implications of the dual role of granule ADP. Biochem Pharmacol
2000;59:1345–55.
54. Gils A. The pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of monoclonal antibodies as
PAI-1 inhibitors. Verh K Acad Geneeskd Belg 2006;68:179 –98.
55. Kung SH, Hagstrom JN, Cass D, Tai SJ, Lin HF, Stafford DW,
et al. Human factor IX corrects the bleeding diathesis of mice
with hemophilia B. Blood 1998;91:784 –90.
56. Liao D, Heiss G, Chinchilli VM, Duan Y, Folsom AR, Lin HM,
et al. Association of criteria pollutants with plasma hemostatic/
inflammatory markers: a population-based study. J Expo Anal
Environ Epidemiol 2005;15:319 –28.
57. Aukrust P, Waehre T, Damas JK, Gullestad L, Solum NO.
Inflammatory role of platelets in acute coronary syndromes.
Heart 2001;86:605– 6.
58. Mueller C, Neumann FJ, Hochholzer W, Trenk D, Zeller T,
Perruchoud AP, et al. The impact of platelet count on mortality

59.

60.

61.

62.

63.

64.

65.

66.

67.

68.

69.

70.

71.

72.

73.

74.

75.

76.

in unstable angina/non-ST-segment elevation myocardial
infarction. Am Heart J 2006;151:1214 –7.
Weinberger I, Fuchs J, Davidson E, Rotenberg Z. Circulating
aggregated platelets, number of platelets per aggregate, and
platelet size during acute myocardial infarction. Am J Cardiol
1992;70:981–3.
Kilicli-Camur N, Demirtunc R, Konuralp C, Eskiser A, Basaran
Y. Could mean platelet volume be a predictive marker for acute
myocardial infarction? Med Sci Monit 2005;11:CR387–92.
Yip HK, Chang LT, Sun CK, Chen MC, Yang CH, Hung WC, et al.
Platelet activity is a biomarker of cardiac necrosis and predictive of
untoward clinical outcomes in patients with acute myocardial infarction
undergoing primary coronary stenting. Circ J 2006;70:31–6.
Pope CA III, Hansen ML, Long RW, Nielsen KR, Eatough NL,
Wilson WE, et al. Ambient particulate air pollution, heart rate
variability, and blood markers of inflammation in a panel of
elderly subjects. Environ Health Perspect 2004;112:339 – 45.
Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner
DD. Pro-coagulant state resulting from high levels of soluble
P-selectin in blood. Proc Natl Acad Sci USA 2000;97:13835– 40.
Blann AD, Li-Saw-Hee F, Lip GY, Minamino T, Kitakaze M,
Sanada S, et al. Increased membrane and soluble P-selectin in
atrial fibrillation. Circulation 1999;100:e86 –7.
Yu TH, Chua S, Cheng CI, Liu WH, Chiu CA, Yang CH, et al.
Concentration of soluble P-selectin and white blood cell counts
in infarct coronary arteries in patients with acute myocardial
infarction differ from the systemic circulation. Chang Gung
Med J 2006;29:169 –74.
Liu WH, Yang CH, Yeh KH, Chang HW, Chen YH, Chen SM,
et al. Circulating levels of soluble P-selectin in patients in the
early and recent phases of myocardial infarction. Chang Gung
Med J 2005;28:613–20.
Woollard KJ, Kling D, Kulkarni S, Dart AM, Jackson S, ChinDusting J. Raised plasma soluble P-selectin in peripheral arterial
occlusive disease enhances leukocyte adhesion. Circ Res 2006;
98:149 –56.
Draz N, Hamdy MS, Gomaa Y, Ramzy AA. Soluble P-selectin is
a marker of plaque destabilization in unstable angina. Egypt
J Immunol 2003;10:83–7.
Khandoga A, Stampfl A, Takenaka S, Schulz H, Radykewicz R,
Kreyling W, et al. Ultrafine particles exert prothrombotic but not
inflammatory effects on the hepatic microcirculation in healthy
mice in vivo. Circulation 2004;109:1320 –5.
Stegnar M, Vene N, Bozic M. Do haemostasis activation markers
that predict cardiovascular disease exist? Pathophysiol Haemost
Thromb 2003;33:302– 8.
Nadziejko C, Fang K, Chen LC, Cohen B, Karpatkin M, Nadas A.
Effect of concentrated ambient particulate matter on blood coagulation parameters in rats. Res Rep Health Eff Inst 2002;111:7–29.
Dahm A, Van HV, Bendz B, Rosendaal F, Bertina RM, Sandset
PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003;101:4387–92.
Abe Y, Nakamura H, Yoshino O, Oya T, Kimura T. Decreased
neural damage after spinal cord injury in tPA-deficient mice.
J Neurotrauma 2003;20:43–57.
Trost S, Pratley R, Sobel B. Impaired fibrinolysis and risk for
cardiovascular disease in the metabolic syndrome and type 2
diabetes. Curr Diab Rep 2006;6:47–54.
Ryan KL, Cortez DS, Dick EJ Jr, Pusateri AE. Efficacy of
FDA-approved hemostatic drugs to improve survival and reduce
bleeding in rat models of uncontrolled hemorrhage. Resuscitation 2006;70:133– 44.
Lee DH, Blajchman MA. Animal models. In: Michelson AD, ed.
Platelets. San Diego, Calif: Academic Press, 2002:357– 66.

